The inhibition of either BRAF or MEK in melanoma patients is assumed to result in an enhanced tumor antigen expression or the release of these antigens caused by cell death, which is then followed by an increased T-cell infiltration [6, 7, 25]. This evidence concerns the gene BRAF and melanoma.